Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT07292818 · ClinicalTrials.gov registry record · Phase 1

Hyaluronic Acid-based Gel Spacers in Gynecologic Malignancies

A Phase 1 study of Cervix Cancer, sponsored by UNC Lineberger Comprehensive Cancer Center.

Recruiting
Registry status
Phase 1
Development phase
14
Enrollment target
1
Study location

NCT07292818: Recruiting Phase 1 study of Cervix Cancer, sponsored by UNC Lineberger Comprehensive Cancer Center.

NCT07292818 is a Phase 1 study of Cervix Cancer that is actively recruiting participants, run by UNC Lineberger Comprehensive Cancer Center. The registered enrollment target is 14 participants, below the 66-participant average among 7 other Cervix Cancer trials with a reported enrollment target (79% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT07292818, a Phase 1 study of Cervix Cancer, is actively recruiting participants, sponsored by UNC Lineberger Comprehensive Cancer Center.

RECRUITING
Registry status
Phase 1
Development phase
14 participants
Enrollment target
1
Study location

Study Summary

This pilot feasibility study evaluates the use of a hyaluronic acid-based spacing gel (Barrigel) in participants with cervical cancer undergoing chemoradiotherapy (chemoRT), including brachytherapy, as part of standard care. The primary goal is to assess feasibility. Other goals include determining whether gel placement can reduce radiation dose to nearby healthy organs (organs at risk, OAR) and improve delivery of the prescribed radiation dose to the tumor. In cervical cancer, the radiation dose to the tumor is often limited by the risk of exposing nearby sensitive organs, such as the rectum, bladder, and other pelvic structures. Vaginal packing techniques and specialized devices are used to protect these organs and ensure effective treatment. Gel spacers are inserted before radiation therapy to create space between the rectum and the cervix, reducing radiation exposure to healthy tissue. Already widely used in prostate cancer treatment in the U.S., gel spacers may also help improve tumor control and reduce treatment-related toxicity in cervical cancer.

Primary Outcome

The NCI Common Terminology Criteria for Adverse Events (NCI-CTCAE) is a descriptive terminology that can be utilized for Adverse Event (AE) reporting. A grading (severity) scale is provided for each AE term. Grade 1 Mild; asymptomatic or mild symptoms; clinical or diagnostic observations only; intervention not indicated. Grade 2 Moderate; minimal, local or noninvasive intervention indicated; limiting age-appropriate instrumental Activities of Daily Living (ADL). Grade 3 Severe or medically signi

Conditions Studied

Interventions

  • DEVICE Barrigel gel spacer

Study Locations (1)

North Carolina

  • Lineberger Comprehensive Cancer Center at University of North Carolina, Chapel Hill - Chapel Hill

Trial Details

FieldValue
Enrollment Target 14 participants
Start Date 2026-02-02
Est. Completion 2030-10-30
Phase Phase 1

What NCT07292818 shows while recruiting

NCT07292818 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 14 participants, a relatively small participant target, below the 66-participant average among 7 other Cervix Cancer trials with a reported enrollment target (79% lower).

The record links to 1 condition, with Cervix Cancer appearing as the primary indexed condition, and to 1 intervention - of which Barrigel gel spacer is the first listed.

NCT07292818 reports a single indexed study location in North Carolina.

Frequently Asked Questions

What is clinical trial NCT07292818 about?

NCT07292818 is a clinical study titled "Hyaluronic Acid-based Gel Spacers in Gynecologic Malignancies". This pilot feasibility study evaluates the use of a hyaluronic acid-based spacing gel (Barrigel) in participants with cervical cancer undergoing chemoradiotherapy (chemoRT), including brachytherapy, as part of standard care. The primary goal is to assess feasibility. Other goals include determining...

What is the current status of trial NCT07292818?

This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 14 participants. The study started on 2026-02-02. Estimated completion is 2030-10-30.

What conditions does trial NCT07292818 study?

This clinical trial studies the following conditions: Cervix Cancer.

What interventions are being tested in trial NCT07292818?

The interventions under investigation include: Barrigel gel spacer (DEVICE).

Who is sponsoring clinical trial NCT07292818?

This trial is sponsored by UNC Lineberger Comprehensive Cancer Center, which has 366 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT07292818 being conducted?

This trial has 1 study location across North Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Cervix Cancer

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT02523092 · 14 participants · Phase 4

    Use of CXCL9 as a Biomarker of Acthar Efficacy

  • NCT04263285 · 14 participants · NA

    Treatment of Depression Post-SCI

  • NCT04743271 · 14 participants · NA

    Food and Circadian Timing

  • NCT05065671 · 14 participants · Phase 1

    Microbiome Derived Metabolism and Pharmacokinetics

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT06358040 · started 2026-10 · NA

    Opioid Dispenser for Microdiscectomy/Laminectomy

Source: ClinicalTrials.gov NCT07292818, the US trial registry maintained by the National Library of Medicine. NCT07292818 (small enrollment · single site footprint · recruiting) retrieved and formatted by PlainTrial, see methodology.